688373 Shanghai Micurx Pharmaceutical
- 4.67
- -0.04-0.85%
Shanghai Micurx Pharmaceutical News
Mengke Pharmaceutical: Revenue of about 33.02 million yuan in the first quarter of 2024 increased 91.10% year-on-year
SHANGHAI, April 28, 2024/PRNewswire/ -- On the evening of April 25, the company released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 33.0161,000 yuan, an increase of 91.10% over the previous year; realized net profit to mother of 102.1366 million yuan; and total R&D investment of 84.646,900 yuan, an increase of 94.73% over the previous year. Evidence-based medical research continues to advance, accelerating the release of clinical potential. The company's first commercial product, contizolamide tablets, is a new generation of oxazolidinone antimicrobials independently designed and developed by the company, which can be used to treat complex skin and soft tissues
Mengke Pharmaceutical (688373.SH) announced first-quarter results with a net loss of 102 million yuan
Mengke Pharmaceutical (688373.SH) released its report for the first quarter of 2024. The company achieved operating income of 3 during the reporting period...
Mengke Pharmaceutical (688373.SH): The ban on 2.631 million restricted shares was lifted on April 23
Gelonghui, April 12丨Mengke Pharmaceutical (688373.SH) announced that the total number of shares in circulation during the current stock listing was 2.631 million shares. The stock listing and circulation date is April 23, 2024.
Mengke Pharmaceutical (688373.SH): Shareholders, directors and executives completed a plan to increase their shareholding in the company
Gelonghui, April 12, 丨 Mengke Pharmaceutical (688373.SH) announced that as of April 11, 2024, the increase holder had accumulated 569,800 shares of the company's shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.087% of the company's total share capital, with a total increase of 2,951,649 yuan. The implementation of this holdings increase plan has been completed. Entities of this increase include some shareholders, directors and senior management of 5% or more of the company, including: MICURX (HK) LIMITED (hereinafter referred to as “Mengke Hong Kong”), the chairman of the company
What Shanghai MicuRx Pharmaceutical Co., Ltd.'s (SHSE:688373) 26% Share Price Gain Is Not Telling You
Shanghai MicuRx Pharmaceutical Co., Ltd. (SHSE:688373) shareholders are no doubt pleased to see that the share price has bounced 26% in the last month, although it is still struggling to make up recen
Mengke Pharmaceutical (688373.SH): Relevant shareholders increased their total shares by 0.04%
Gelonghui, April 8, 丨 Mengke Pharmaceutical (688373.SH) announced that as of April 8, 2024, the increase holder had accumulated 269,800 shares of the company's shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.04% of the company's total share capital. The total amount of increase in holdings was 13.297.39 million yuan, which has exceeded 50% of the lower limit of 500,000 shares in this increase plan. The implementation of this holdings increase plan has not yet been completed, and the entities that have increased their holdings will continue to implement the holdings increase in accordance with the holdings increase plan. The entities of this increase in holdings include some shareholders, directors and senior management personnel of 5% or more, including: Company 5
Mengke Pharmaceutical (688373.SH) announced 2023 annual results, and net loss increased to 421 million yuan
Mengke Pharmaceutical (688373.SH) disclosed its 2023 annual report. The company achieved an operating income of 90 during the reporting period...
Is Shanghai MicuRx Pharmaceutical (SHSE:688373) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it seems the smart money knows that debt - which is usu
Mengke Pharmaceutical (688373.SH) had a net loss of 418 million yuan in 2023
According to the Zhitong Finance App, Mengke Pharmaceutical (688373.SH) released its 2023 annual performance report, achieving total revenue of 97.7764 million yuan, an increase of 88.31% over the previous year. Net loss attributable to owners of the parent company was $418 million. Net loss attributable to owners of the parent company after deducting non-recurring profit and loss of $451 million. The main reason for the decline in profit during the reporting period was that during the reporting period, in order to enhance its core competitiveness, the company further enriched its new drug development pipeline, continued to advance R&D projects, several innovative drugs were in a critical clinical trial stage, R&D expenditure further increased, and the company's overall R&D investment
Mengke Pharmaceutical (688373.SH): Some shareholders, directors and executives plan to increase their holdings by 500,000 shares to 1 million shares
Gelonghui, Feb. 6: Mengke Pharmaceutical (688373.SH) announced that some of the company's shareholders, directors and senior management plan to increase their holdings of the company by means of centralized bidding within 6 months from February 7, 2024 through the Shanghai Stock Exchange System. They intend to increase their holdings by no less than 500,000 shares and no more than 1 million shares. There is no fixed price or price range for this increase in holdings. The aforementioned holdings increase entities will take the opportunity to implement plans to increase their holdings according to the company's stock price fluctuations and overall capital market trends.
Mengke Pharmaceutical won the BioPR - First Biomedical Industry Best Communication Case Gold Award and Excellence Award
SHANGHAI, January 23, 2024/PRNewswire/ -- On January 19, 2024, the first best communication case in the biomedical industry was revealed in Shanghai, co-sponsored by BioPR, R&D, and Zhangjiang Pharmaceutical Valley, and supported by Shangfang Group's “Zhang Jiang Zhishang” and ZJ-BBC. Mengke Pharmaceutical won the Gold Award for the Best Corporate Promotional Video of the Year and the Best Product Communication Case of the Year Award. “This is a terrible war for life.” Since the day antibiotics were discovered, the problem of bacterial drug resistance has also followed. Bacteria have continued to evolve, yet the pace of human discovery of antibiotics has appeared in the past ten years
Mengke Pharmaceutical (688373.SH) issued a forecast loss. It is expected to have a huge loss of about 430 million yuan to 360 million yuan in 2023, an increase in losses over the previous year
According to Zhitong Finance App News, Mengke Pharmaceutical (688373.SH) released its 2023 annual performance forecast. The company expects net loss attributable to shareholders of listed companies to be about 430 million yuan to 360 million yuan in 2023, an increase in year-on-year losses; net losses attributable to shareholders of listed companies in 2023 after deducting non-recurring profits and losses are expected to be about 460 million yuan to 390 million yuan, an increase in year-on-year losses. Although the company's revenue increased during the reporting period, R&D expenditure continued to increase as the clinical progress of the company's ongoing research projects continued to advance and the size of the R&D personnel team expanded. At the same time, along with
Mengke Pharmaceutical (688373.SH): 2023 pre-loss increased by 63.41% to 95.19%
Gelonghui, January 22丨Mengke Pharmaceutical (688373.SH) announced its 2023 annual results forecast. According to preliminary estimates by the finance department, it is expected to achieve operating income of about 890 million yuan to 90.2 million yuan in 2023. Compared with the same period last year, it will increase 40.7933 million yuan to 43.7933 million yuan, an increase of 84.62% to 90.84% over last year. The net profit attributable to shareholders of listed companies in 2023 is estimated to be around $430,000 to -360.01 million yuan, an increase of 13 over the same period last year
Shanghai MicuRx Pharmaceutical Co., Ltd.'s (SHSE:688373) Market Cap Dropped CN¥360m Last Week; Retail Investors Bore the Brunt
Key Insights Shanghai MicuRx Pharmaceutical's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public The top 7 shareholders own
MicuRx Pharma Plans $80 Million Capital Injection in US Subsidiary
Shanghai MicuRx Pharmaceutical (SHA:688373) plans to invest $80 million in its wholly-owned US subsidiary, MicuRx Pharmaceuticals Inc., according to a filing on Wednesday. The capital increase will su
Mengke Pharmaceutical (688373.SH): Plans to increase capital of a wholly-owned subsidiary in the US by 80 million US dollars
Gelonghui on December 19丨Mengke Pharmaceutical (688373.SH) announced that it plans to use its own capital to increase the capital of its wholly-owned subsidiary MiCurX Pharmaceuticals, Inc., in the US. The investment is a cash contribution, and the proposed investment amount is US$80 million.
Mengke Pharmaceutical (688373.SH): Terminate the issuance of shares to specific targets using simplified procedures in 2023
Gelonghui (688373.SH) announced on December 19|Mengke Pharmaceutical () announced that based on factors such as the capital market environment and funding arrangements, and according to the company's management needs, the company decided to terminate the issuance of shares to specific targets through simple procedures in accordance with the authorization of the 2022 Annual General Meeting of Shareholders after careful analysis.
Mengke Pharmaceutical: MRX-4 sequential contizolamide tablets for injectable drug resistant gram-positive bacterial infections approved
SHANGHAI, November 24, 2023/PRNewswire/ -- Recently, Shanghai Mengke Pharmaceutical Co., Ltd. (stock code: 688373.SH) (hereinafter referred to as the “Company”) received the “Drug Clinical Trial Approval Notice” approved and issued by the China National Drug Administration (NMPA) concerning contizolamide tablets and MRX-4 for injection for sequential treatment of drug-resistant gram-positive bacterial infections. Contizolid tablets and MRX-4 are innovative oxazolidinone antimicrobial drugs with global intellectual property rights developed independently by the company. Contizolid tablets (400mg) were released on June 1, 2021
MicuRx Pharmaceutical Gets Nod to Trial New Antibiotic
Shanghai MicuRx Pharmaceutical (SHA:688373) has obtained approval from China's National Medical Products Administration to carry out a clinical trial of its new antibiotic. The Chinese drugmaker's inj
Mengke Pharmaceutical (688373.SH): Injectable MRX-4 sequential contizolamide tablets for drug resistant gram-positive bacteria infection indications obtained a clinical trial approval notice
Gelonghui November 23丨Mengke Pharmaceutical (688373.SH) announced that it has recently received the “Drug Clinical Trial Approval Notice” approved and issued by China's State Drug Administration on contizolamide tablets and injectable MRX-4 for treatment of drug-resistant gram-positive bacterial infections. Contizolid tablets and MRX-4 for injection are innovative oxazolidinone antimicrobial drugs independently developed by the company and have global intellectual property rights.
Analysis
Price Target
No Data
